MedPath

Testing the Efficacy of Photobiomodulation Therapy and Hyaluronic Acid Gel on Post-surgical Healing After Gingivectomy

Not Applicable
Recruiting
Conditions
Gingival Hyperplasia
Gingival Hypertrophy
Gingival Enlargement
Gingival Overgrowth
Photobiomodulation Therapy
Low-level-laser Theraphy
Interventions
Drug: Gengigel
Device: LASER
Registration Number
NCT07169357
Lead Sponsor
Beirut Arab University
Brief Summary

This study consists of random patient selection and allocating them in 3 different groups. After being fit to be included according to the protocol's criteria and signing an informed consent, patients will be distributed after performing a dental surgery known as gingivectomy. Gingivectomy has been classified as the gold standard treatment option for the control of gingival enlargement. Wound recovery after gingivectomy and gingivoplasty occurs by secondary intention healing, thus post-surgical wounds can be strongly associated with discomfort, pain and delayed healing. For that reason, the first group will consist of 13 patients who will be exposed to hyaluronic acid gel or gingigel and photobiomodulation therapy to see if there is significant results in the post-operative healing phase. The second group will also consist of 13 patients who will undergo only photobiomodulation therapy. While the third group will have no clinical supportive care besides follow-up and analgesics upon request.

All the values will be determined by using scores such as Visual analogue scale for pain, Landry's index for healing assessment and oral health quality of life, which consists of 14 questions to asses the enhancement of everyday problems affected by dental situations.

Each case will be followed-up for 3 months post-operative.

Detailed Description

The study group consisted of thirty-nine surgical gingivectomy wound sites on patients presenting with gingival hypertrophy on maxillary or mandibular anterior region. Groups will be randomly and equally divided into three groups, Group-A (Test Group 1): Surgical sites after gingivectomy procedures will be irradiated with diode laser (Photobiomodulation therapy) at (940 nm, 0.21 W) with a fiber tip diameter of 400μm for 30 seconds, then covered with HA Gel. Group-B (Test Group 2): Surgical sites will be irradiated with diode laser only at (940 nm, 0.21 W). Group-C (Control Group): No post-surgical therapy will be performed. Wound healing was assessed by implementing Landry, Turnbull and Howley Healing index, while pain perception was objectively evaluated by the patients using the visual analog scale (VAS). To further evaluate the patient's quality of life, Oral Health Impact Profile (OHIP-14) records will be obtained before and after gingivectomy.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
38
Inclusion Criteria
  • Patient health ASA I, II
  • Average age from 18 to 40 years
  • Both genders
  • Chronic inflammatory gingival enlargement
  • Adequate amount of keratinized tissue.
  • Well educated patients as post-operative instructions need to be followed precisely.
Exclusion Criteria
  • Smokers
  • Bad oral hygiene
  • Allergy to Hyaluronic acid or cosmetic fillers containing H.A
  • Any patient under oral contraceptives or immunosuppressive drugs
  • Patients undergoing radiotherapy or chemotherapy
  • Pregnant or lactating mothers
  • Mentally disturbed patients
  • Excessive gag reflex
  • Patients who refuse to sign informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
test group (Group A)GengigelSurgical sites after gingivectomy procedures will be irradiated with diode laser (Photobiomodulation therapy) then covered with HA Gel.
test group (Group A)LASERSurgical sites after gingivectomy procedures will be irradiated with diode laser (Photobiomodulation therapy) then covered with HA Gel.
test group (Group B)LASERSurgical sites will be irradiated with diode laser only
Primary Outcome Measures
NameTimeMethod
Landry's healing indexWound healing assessed by implementing Landry, Turnbull and Howley Healing index on the 3rd, 7th, 14th, 21st day, 1 month, 2 months and 3 months after the post-surgical procedure.

to asses the wound healing progress post-surgically in the 3 groups and see how photobiomodulation therapy and the application of hyaluronic acid can enhance the post-operative period.

Five variables are assessed: tissue color, bleeding on palpation, the presence of granulation tissue, the incision margin and suppuration. It ranges from 1 to 5, with 1 indicating poor healing and 5 indicating excellent healing

Visual analogue scalePain perception will be evaluated by using the visual analog scale on the 3rd, 7th, 14th, 21st day and 1 month of periodic follow-up

to asses the subjected level of pain by the patient throughout the healing process with a minimum score of 0 meaning no pain (best) and a maximum score of 10 meaning severe pain (worse)

Secondary Outcome Measures
NameTimeMethod
Oral health impact profile 14 questionspre-operative post-operative - on the 7th day - on the 14th day

to asses the quality of life of patients prior the surgery due to their condition to asses the enhancement of the patient's condition after the surgery and asses how the post-operative interventions bettered their post-operative experience.

To asses the condition you sum the numerical values of each of the 14 items with a 5-point likert scale 0= never 1= hardly ever 2= ocassionally 3=fairly often 4= very often then you sum the scores of all 14 question to get a total score from 0-56. closer to 56 = greater negative impact of oral health problems on the quality of life closer to 0 =better oral-health related quality of life

Trial Locations

Locations (1)

Beirut Arab University

🇱🇧

Beirut, Lebanon

Beirut Arab University
🇱🇧Beirut, Lebanon
Hanan Rabih Danaf Naim, masters in periodontology
Contact
0096170493218
hrd135@student.bau.edu.lb
Hanan R Danaf Naim, masters
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.